rs5068 — NPPA

3'UTR variant that disrupts miR-425 binding, increasing atrial natriuretic peptide levels and conferring cardioprotection against hypertension and metabolic syndrome

See your personal result for NPPA

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

NPPA rs5068: Your Heart's Built-In Blood Pressure Brake

The heart is not only a pump — it's an endocrine organ that actively regulates blood pressure. When the atria stretch under elevated pressure, cardiac cells release atrial natriuretic peptide (ANP)11 atrial natriuretic peptide (ANP)
a hormone that signals the kidneys to excrete sodium and water, dilates blood vessels, and suppresses the renin-angiotensin system. ANP is the body's built-in counter-regulatory brake against hypertension. The rs5068 variant in the 3' untranslated region of the NPPA gene determines how efficiently this brake operates. Carriers of the minor G allele produce substantially more ANP — and enjoy a broad spectrum of cardiovascular and metabolic benefits as a result.

The Mechanism

The 3' UTR of an mRNA contains binding sites for microRNAs22 microRNAs
small non-coding RNA molecules that bind to mRNA and suppress its translation into protein. The rs5068 A allele (carried by ~89% of people) contains a perfect binding site for miR-425, which is expressed in cardiac atria and ventricles. When miR-425 binds, it silences NPPA mRNA — reducing ANP secretion by up to 56% in experimental cardiomyocytes.

The G allele disrupts this binding site through a single nucleotide change. In cells carrying the G allele, miR-425 cannot bind, and NPPA mRNA escapes suppression. In vitro33 In vitro
laboratory cell studies confirmed that miR-425 reduces NPPA expression in A-allele constructs but not G-allele constructs (P = 0.005). In physiologic studies, AG individuals showed 32-50% higher circulating Nt-proANP compared to AA individuals — a difference comparable in magnitude to the ANP change induced by a 20-fold dietary salt variation.

The Evidence

The foundational Nature Genetics GWAS44 Nature Genetics GWAS
a genome-wide association study pooling 29,717 European-ancestry participants established rs5068 as one of the strongest genetic determinants of circulating natriuretic peptide levels (P = 8×10⁻⁷⁰ for ANP; P = 3×10⁻¹² for BNP). The G allele was associated with lower systolic blood pressure (P = 2×10⁻⁶), lower diastolic blood pressure (P = 1×10⁻⁶), and a 15% lower odds of hypertension (OR 0.85, 95% CI 0.79-0.92).

A community-based JACC study55 community-based JACC study
n=1,608 residents of Olmsted County, Minnesota, followed prospectively found G allele carriers had lower systolic blood pressure (−4.3 mmHg), lower BMI (−1.2 kg/m²), smaller waist circumference (−2.5 cm), lower obesity odds (OR 0.54), higher HDL cholesterol (+2.5 mg/dL), lower CRP, and strikingly lower odds of myocardial infarction (OR 0.29, P = 0.042).

In a Mediterranean population66 Mediterranean population
n=804 adults from rural Sicily, adjusted for age, sex, and BMI, G allele carriers showed 6.0 mmHg lower systolic blood pressure (P = 0.02), 3.0 mmHg lower diastolic (P = 0.03), and a 59% lower odds of hypertension (OR 0.41, 95% CI 0.20-0.83).

The Malmö Preventive Project77 Malmö Preventive Project
n=968 non-diabetic older adults with echocardiography data demonstrated that G allele carriers had significantly less left ventricular hypertrophy — an ominous cardiac remodeling response to chronic pressure overload — with an OR of 0.47 (95% CI 0.25-0.89).

Protection extends to metabolic health. A large Swedish prospective cohort88 large Swedish prospective cohort
n=27,307 from the Malmö Diet and Cancer Study, 14 years follow-up found G allele carriers had 12% lower hazard of developing type 2 diabetes (HR 0.88, 95% CI 0.78-0.99). ANP directly activates hormone-sensitive lipase in adipose tissue via a cGMP-dependent pathway, promoting fat oxidation and improving insulin sensitivity.

The protective effect extends across ethnicities. In African American MESA participants99 African American MESA participants
n=1,631 from the Multi-Ethnic Study of Atherosclerosis, G allele carriers had lower metabolic syndrome prevalence (23% vs 38%) and lower triglycerides, though the blood pressure association was not significant in this population.

Practical Actions

The AA genotype — carried by most people — means the miR-425 brake operates fully, keeping ANP levels lower. This doesn't cause disease on its own, but it means the natural ANP-mediated counterbalance to salt loading and blood pressure elevation is somewhat blunted. Practical strategies center on reducing the need for ANP (lower sodium load, support vascular tone through dietary nitrates) and monitoring blood pressure proactively.

G allele carriers produce more ANP and enjoy measurably lower blood pressure and metabolic protection. No specific interventions are needed for the protective genotype — the key insight is understanding why your blood pressure runs lower and why your metabolic profile is favorable.

Interactions

NPPA and NPPB (which encodes BNP) lie in tandem on chromosome 1p36 and are co-regulated. The NPPB variant rs198389 similarly influences BNP levels and blood pressure. Haplotype analyses show that combinations of NPPA rs5068 G and NPPB rs198389 G produce additive elevations in circulating natriuretic peptides. Sex modifies the metabolic protection: in a general community cohort, the ANP protection from rs5068 was more pronounced in men than women, while BNP protection (rs198389) tended toward women.

Genotype Interpretations

What each possible genotype means for this variant.

AA Baseline ANP Activity Normal

Normal ANP levels — full miR-425 suppression of NPPA expression

You have two copies of the common A allele. The microRNA miR-425 can bind normally to your NPPA mRNA, keeping atrial natriuretic peptide production at its baseline level. About 89% of people share this genotype. Your cardiovascular risk from this variant alone is not elevated — this simply means you lack the additional miR-425-escape protection conferred by the G allele.

GG Maximum ANP Activity Beneficial

Two G alleles — maximum escape from miR-425 suppression, highest circulating ANP

GG homozygotes are rare — roughly 0.1-0.4% of most populations — so few studies have separately reported their phenotype. The effect follows an additive pattern: GG individuals are expected to have the highest circulating ANP levels, with both copies of NPPA mRNA fully resistant to miR-425-mediated silencing.

Given the strong dose-response seen for the G allele across multiple large cohorts, GG homozygotes likely have the lowest blood pressure, the most favorable lipid and metabolic profiles, and the lowest cardiometabolic risk attributable to this locus.

One important note: extremely high ANP levels in the context of an underlying cardiac disease (such as heart failure or atrial fibrillation) may sometimes be a marker of cardiac stress. The elevated ANP in GG homozygotes is driven by constitutively higher expression, not cardiac injury, but this distinction is worth knowing if you are evaluated for elevated natriuretic peptides in a clinical setting.

AG Enhanced ANP Activity Beneficial

One G allele — partial escape from miR-425 suppression, ~30-50% higher ANP

The G allele prevents miR-425 from binding your NPPA mRNA, allowing your heart to produce substantially more ANP — your body's natural anti-hypertensive hormone. This enhanced natriuretic peptide activity promotes sodium and water excretion by the kidneys, relaxes blood vessel walls, and suppresses the renin-angiotensin-aldosterone system.

In a Mediterranean cohort of 804 adults, AG/GG carriers had 6.0 mmHg lower systolic blood pressure and 59% lower odds of hypertension (OR 0.41). In the Framingham-like Olmsted County study (n=1,608), AG/GG carriers had lower BMI, less obesity, smaller waist circumference, higher HDL, lower CRP, and strikingly lower odds of myocardial infarction (OR 0.29). The Swedish Malmö cohort (n=27,307) found 12% lower hazard of type 2 diabetes over 14 years (HR 0.88). These are not trivial effects — this is one of the most consistently replicated cardioprotective common variants.